Literature DB >> 334688

Double-blind study with two butyrophenone derivatives: bromperidol vs. haloperidol.

W Pöldinger, E Bures, H Haage.   

Abstract

The present report deals with a double-blind study comparing the new butyrophenone derivative, bromperidol, with haloperidol as the reference substance. Both substances were found to be highly effective in the treatment of psychotic syndromes belonging predominantly to the schizophrenia group. Certain clues, including the onset of action, seem to be indicative of the superiority of bromperidol. No differences between the two substances were observed with respect to side effects and general tolerability.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 334688     DOI: 10.1159/000468306

Source DB:  PubMed          Journal:  Int Pharmacopsychiatry        ISSN: 0020-8272


  3 in total

Review 1.  Bromperidol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in psychoses.

Authors:  P Benfield; A Ward; B G Clark; S G Jue
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

2.  Bromperidol, a new butyrophenone neuroleptic: a review.

Authors:  B Dubinsky; J L McGuire; C J Niemegeers; P A Janssen; H S Weintraub; B E McKenzie
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

Review 3.  Bromperidol decanoate (depot) for schizophrenia.

Authors:  Marianna Purgato; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2012-11-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.